Provided by Tiger Trade Technology Pte. Ltd.

Natera

319.77
-6.4900-1.99%
Volume:353.91K
Turnover:112.80M
Market Cap:45.80B
PE:-232.92
High:325.65
Open:320.41
Low:316.00
Close:326.26
52wk High:343.18
52wk Low:157.43
Shares:143.22M
Float Shares:139.00M
Volume Ratio:0.54
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3729
EPS(LYR):-1.5269
ROE:-12.54%
ROA:-8.08%
PB:25.14
PE(LYR):-209.43

Loading ...

Natera Partners with Eledon to Supply Prospera Monitoring for Planned Phase 3 Kidney Transplant Trial

Reuters
·
Jun 25

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

THOMSON REUTERS
·
Jun 25

Natera - Eledon to Initiate Phase 3 Kidney Transplant Trial in Late 2026

THOMSON REUTERS
·
Jun 25

Movement Alert|Natera Rises 9.14% in Regular Trading, Signatera MRD Test Secures Regulatory Approval in Japan

Market Focus
·
Jun 25

Street View: Japan Nod for Natera's Cancer Test Meaningful, but Payoff Seen Later

Reuters
·
Jun 24

Sector Update: Healthcare Stocks Rise Pre-Bell Wednesday

MT Newswires Live
·
Jun 24

Natera : Barclays Cuts Target Price to $260 from $280

THOMSON REUTERS
·
Jun 24

Natera announces Signatera receives regulatory approval in Japan

TIPRANKS
·
Jun 24

BRIEF-Natera Says Signatera Receives Regulatory Approval In Japan For Colorectal Cancer

Reuters
·
Jun 24

Natera Signatera colorectal cancer MRD test wins Japan PMDA approval

Reuters
·
Jun 24

Natera Inc - Natera Expects to Commercially Launch Signatera for Crc in Japan by End of 2026

THOMSON REUTERS
·
Jun 24

Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer

THOMSON REUTERS
·
Jun 24

Natera price target raised to $270 from $250 at BTIG

TIPRANKS
·
Jun 24

Natera Is Maintained at Buy by BTIG

Dow Jones
·
Jun 24

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as AI Spending Concerns Weigh on Technology Shares

MT Newswires Live
·
Jun 23

Sector Update: Healthcare Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Jun 23

Natera Says Signatera Gets NCCN Category 1 Recommendation in Bladder Cancer

MT Newswires Live
·
Jun 23

FDA approves Natera Signatera CDx as companion diagnostic for muscle-invasive bladder cancer

Reuters
·
Jun 23

Natera says NCCN adds Signatera ctDNA-MRD testing to bladder cancer treatment guidelines

Reuters
·
Jun 23

Natera co-founder, Director Sheena Jonathan disposes of common shares worth $330,611.72

Reuters
·
Jun 23